Zacks Research Forecasts Stronger Earnings for Novartis

Novartis AG (NYSE:NVS - Free Report) - Stock analysts at Zacks Research lifted their FY2025 EPS estimates for Novartis in a research note issued to investors on Wednesday, January 15th. Zacks Research analyst E. Bagri now forecasts that the company will earn $8.33 per share for the year, up from their previous forecast of $8.31. The consensus estimate for Novartis' current full-year earnings is $7.63 per share. Zacks Research also issued estimates for Novartis' Q4 2025 earnings at $2.08 EPS, Q3 2026 earnings at $2.39 EPS and Q4 2026 earnings at $2.24 EPS.

Several other brokerages have also recently issued reports on NVS. Erste Group Bank restated a "hold" rating on shares of Novartis in a research note on Tuesday, November 19th. BMO Capital Markets boosted their price objective on shares of Novartis from $118.00 to $120.00 and gave the company a "market perform" rating in a research report on Wednesday, October 30th. Finally, HSBC lowered shares of Novartis from a "hold" rating to a "reduce" rating in a research note on Wednesday, December 4th. Two equities research analysts have rated the stock with a sell rating and seven have issued a hold rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $121.50.

Novartis Stock Performance

NYSE:NVS traded down $0.10 during trading hours on Friday, reaching $97.76. 941,730 shares of the stock were exchanged, compared to its average volume of 1,547,508. Novartis has a 52 week low of $92.35 and a 52 week high of $120.92. The company has a quick ratio of 0.90, a current ratio of 1.11 and a debt-to-equity ratio of 0.55. The stock has a market capitalization of $199.82 billion, a P/E ratio of 11.36, a P/E/G ratio of 1.36 and a beta of 0.57. The firm has a 50 day simple moving average of $100.97 and a 200-day simple moving average of $109.12.

Novartis (NYSE:NVS - Get Free Report) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.06 EPS for the quarter, topping the consensus estimate of $1.94 by $0.12. The business had revenue of $12.82 billion for the quarter, compared to analysts' expectations of $12.62 billion. Novartis had a net margin of 35.96% and a return on equity of 34.80%. During the same quarter last year, the company posted $1.74 earnings per share.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of NVS. Steigerwald Gordon & Koch Inc. grew its holdings in Novartis by 4.8% in the 3rd quarter. Steigerwald Gordon & Koch Inc. now owns 2,091 shares of the company's stock worth $241,000 after buying an additional 95 shares in the last quarter. Centaurus Financial Inc. grew its stake in shares of Novartis by 1.7% in the third quarter. Centaurus Financial Inc. now owns 5,728 shares of the company's stock worth $659,000 after purchasing an additional 98 shares in the last quarter. FLC Capital Advisors increased its holdings in shares of Novartis by 4.4% during the third quarter. FLC Capital Advisors now owns 2,366 shares of the company's stock valued at $272,000 after purchasing an additional 100 shares during the period. Clear Harbor Asset Management LLC raised its stake in shares of Novartis by 2.3% during the third quarter. Clear Harbor Asset Management LLC now owns 4,423 shares of the company's stock valued at $509,000 after purchasing an additional 100 shares in the last quarter. Finally, Allen Wealth Management LLC lifted its holdings in Novartis by 1.8% in the third quarter. Allen Wealth Management LLC now owns 5,788 shares of the company's stock worth $666,000 after purchasing an additional 100 shares during the period. Institutional investors own 13.12% of the company's stock.

About Novartis

Novartis AG engages in the research, development, manufacture, and marketing of healthcare products in Switzerland and internationally. The company offers prescription medicines for patients and physicians. It focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, and oncology, as well as ophthalmology and hematology.